-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34

Benzinga·01/08/2026 13:58:07
Listen to the news
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.